论文信息 - Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). - 字舞流文

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Y. Bang | J. Taieb | M. Dvorkin | R. Wong | S. Lonardi | T. Takano | G. Vaccaro | N. Boku | M. Moehler | H. Coşkun | M. Nechaeva | H. Safran | A. Bragagnoli | I. Conti | M. Ozguroglu | A. Muntean | H. Xiong | Janet Hong | A. C. Gracián | M. Ryu